Read More Pharma Industry News Theriva targets Phase 2/3 VCN-01 trial after early eye-preservation signal Theriva plans a VCN-01 Phase 2/3 retinoblastoma trial after early eye-preservation signals, but its $11.3m cash runway raises the stakes. bySoujanya RaviAugust 14, 2026